NEW YORK and CAESAREA, Israel, Aug.
12, 2019 /PRNewswire/ -- DarioHealth
Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading
global, digital therapeutics company, presented new clinical data
yesterday at the American Association of Diabetes Educators
("AADE") conference in Houston,
Texas, which showed remarkable improvements in average
blood-glucose levels and in-range measurements in patients with
diabetes using Dario's digital therapeutics platform and dedicated
one-on-one personal health coaching.
DarioHealth's digital therapeutics platform delivers
evidence-based interventions to users that are driven by precision
data analytics, high quality software and personalized coaching,
which are available through personalized user membership plans. The
clinical study data presented at the AADE conference included users
enrolled in Dario's full membership plan, which is available to
payers, providers and consumers online.
The results of the study suggest that personal health coaching,
combined with regular health information captured on the Dario app,
such as blood-glucose levels, food and exercise, can significantly
assist diabetes patients in managing and improving their chronic
condition and potentially lower their blood-glucose levels to be in
line with the American Diabetes Association (ADA) suggested A1c
goals of 6.5% (equivalent to 140 mg/dL blood-glucose average) for
certain diabetic patients.
The Dario study was based on the analysis of clinical data of
162 Dario users. In order to establish a baseline blood-glucose
level prior to commencement of the study, the Dario users study
group consistently measured their blood-glucose levels one month
prior to starting the Dario personal coaching program. Once the
study began, these users received regular digital monitoring of
their blood-glucose levels throughout the day, and direct personal
coaching support from a Dario health coach for three months, while
measuring their blood-glucose levels more than 30 times per month,
on average, throughout the study.
The clinical outcomes observed showed that Dario's blood-glucose
monitoring system, coupled with personal Dario coaching,
successfully assisted a large percentage of users in managing their
blood-glucose levels to be in line with what would be considered
pre-diabetes levels:
- 45% (73 out of 162) of the study group reduced their average
blood-glucose levels to under 140 mg/dL, which is considered a
pre-diabetic measurement according to ADA guidelines;
- All study users (162 cohort) reduced their average
blood-glucose levels by 6% (155±42.1 mg/dL) while
participating in the three-month study (compared to a baseline
level of 165±48.7 mg/dL);
- Additionally, a subgroup of 101 users of the 162 cohort began
the study with average blood-glucose levels that exceeded 140 mg/dL
and experienced a 39% increase of in-range blood-glucose
measurements versus the study baseline, and an 11% reduction in
average blood-glucose levels (171±38.0 mg/dL) after
three months (versus the study baseline level of
191±43.5 mg/dL).
Olivier Jarry, President and
Chief Commercial Officer at DarioHealth, commented on the study
saying, "It is a great honor to present the results of this study
at the AADE conference, which shows that personalized coaching,
combined with consistent digital monitoring of blood glucose and
other health and lifestyle parameters, leads to increased user
engagement and better health outcomes for individuals with
diabetes."
"At DarioHealth, it is our objective to set the clinical data
standards in the digital therapeutics industry to help users
achieve meaningful outcomes and improved self-management. We
believe that the results of this study provide further evidence of
the real value that our program delivers to our users," said
Erez Raphael, Chief Executive
Officer of DarioHealth.
"These study results further prove that Dario's diabetes
solutions can assist users in modifying their behavior to achieve
improved glycemic levels. A blood-glucose level of less than
140mg/dL is an important threshold for a diabetes patient, as the
ADA suggests stringent A1c goals of 6.5% (equivalent to 140 mg/dL)
for certain diabetic patients, if such levels can be achieved
without significant hypoglycemia. Moreover, retaining blood glucose
at targeted ADA levels helps people with diabetes avoid serious
complications from their health condition," said Mr. Raphael.
Dario offers a digital blood-glucose monitoring system
accessible through its mobile phone app; modules to regularly
monitor medication, weight, blood pressure, food and exercise;
weekly progress reports; personalized coaching guidance for
individual users; feedback alerts; relevant content delivery and
follow-up with dedicated professionals via in-app chats features,
emails and calls. The results of the study show that combining
digital and human coaching can be an effective tool in promoting
user self-care, which is a central goal of Dario. The system helps
users understand their real-time clinical status, the cause and
effect of different behaviors and how to best manage better their
condition and improve their clinical outcomes.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital
therapeutics company revolutionizing the way people with chronic
conditions manage their health. By delivering evidence-based
interventions that are driven by data, high-quality software and
coaching, we empower individuals to make healthy adjustments to
their daily lifestyle choices to improve their overall health. Our
cross-functional team operates at the intersection of life
sciences, behavioral science and software technology to deliver
highly engaging therapeutic interventions. Dario is one of the
highest-rated diabetes solutions in the market, and its
user-centric MyDario™ mobile app is loved by tens of
thousands of consumers around the globe. DarioHealth is rapidly
moving into new chronic conditions and geographic markets, using a
performance-based approach to improve the health of users managing
chronic disease. To learn more about DarioHealth and its digital
health solutions via the MyDario™ mobile app, please
go to: http://mydario.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company states
that the results of the study suggest that the personal health
coaching, combined with regular health information captured on the
Dario app, such as blood-glucose levels, food and exercise, can
significantly assist diabetes patients in managing and improving
their chronic condition and potentially lower their blood-glucose
levels to pre-diabetic levels, that personalized coaching, combined
with consistent digital monitoring of blood glucose and other
health and lifestyle parameters, leads to increased user engagement
and better health outcomes for individuals with diabetes, the
belief that the results of the study provides further evidence of
the real value that the Company's program delivers to its users and
the belief that the Company's diabetes solutions can assist users
in modifying their behavior to achieve improved glycemic levels, it
is using forward-looking statements. Readers are cautioned that
certain important factors may affect the Company's actual results
and could cause such results to differ materially from any
forward-looking statements that may be made in this news release.
Factors that may affect the Company's results include, but are not
limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com
+1.347.767.4220
Media Inquiries:
Catherine
Polisi Jones
Polisi Jones Communications
cjones@polisijones.com
+1.917.330.8934
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-clinical-study-data-shows-the-dario-membership-program-assists-diabetes-patients-in-achieving-pre-diabetic-blood-glucose-levels-and-consistent-in-range-measurements-300899950.html
SOURCE DarioHealth Corp.